Global Acute Respiratory Distress Syndrome (ARDS) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035

Global Acute Respiratory Distress Syndrome (ARDS) Market Outlook

Thelansis's "Global Acute Respiratory Distress Syndrome (ARDS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential ARDS treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Acute Respiratory Distress Syndrome (ARDS) Overview

Acute respiratory distress syndrome (ARDS) is a life-threatening inflammatory lung injury characterized by diffuse alveolar damage, alveolar-capillary barrier disruption, and protein-rich edema flooding. Driven by dysregulated neutrophilic inflammation, it is triggered by direct pulmonary insults like pneumonia or indirect systemic insults like sepsis. Diagnosis combines bilateral imaging infiltrates and the exclusion of primary hydrostatic cardiogenic edema. To accommodate modern global settings, updated consensus criteria expand the classic Berlin Definition by validating non-invasive SpO2/FiO2 (SF) ratios alongside PaO2/FiO2 thresholds, and acknowledging High-Flow Nasal Oxygen (HFNO) at flow rates of 30 L/min or greater as an acceptable diagnostic modality. Management centers on lung-protective mechanical ventilation, restricting tidal volumes to 6 mL/kg of predicted body weight, limiting plateau pressures, and titrating individualized PEEP. Prone positioning for moderate-to-severe disease significantly improves survival. Pharmacotherapy relies on early dexamethasone protocols, a conservative fluid approach, and neuromuscular blockade, with extracorporeal membrane oxygenation reserved for refractory hypoxemia. Prognosis carries substantial mortality, requiring intensive multidisciplinary ICU-based care.

Key Highlights

• In the US, incident ARDS cases are projected to increase from 547.3K in 2025 to 586.7K by 2035, reflecting a modest growth trajectory (0.7% CAGR) linked to aging population and rising critical illness incidence.
• Despite high incidence, treatment remains entirely supportive, with no approved disease-modifying therapies, representing a major unmet clinical need.
• Increasing research focus on anti-inflammatory, endothelial-stabilizing, and regenerative therapies is expected to shape future treatment paradigms.

Market Overview

• The ARDS market in Italy is projected to grow from $62M in 2025 to $122M by 2035, reflecting moderate-to-strong growth driven by critical care advancements and supportive therapy utilization.
• Market growth is not directly correlated with incidence alone but influenced by:
• Increased use of advanced ICU interventions (e.g., ECMO, ventilation technologies)
• Rising healthcare expenditure in critical care settings
• Current market value is largely derived from supportive care infrastructure (ventilation systems, ICU management), rather than pharmacological therapies.
• Future market expansion will depend on the development and adoption of targeted therapies addressing the underlying inflammatory and vascular mechanisms of ARDS.

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Companies Mentioned

• Changchun Tuohua Pharmaceutical Co., Ltd.
• Breathe Biologics, Inc.
• Staidson (Beijing) Biopharmaceuticals Co., Ltd.
• EnliTISA (Shanghai) Pharmaceutical Co., Ltd.
• HTIC, Inc
• BioAegis Therapeutics Inc.
• Direct Biologics, LLC
• Implicit Bioscience
• Dompe Farmaceutici S.p.A
• Pharmazz, Inc.
• Aqualung Therapeutics Corp.
• Arch Biopartners Inc.
• Vasomune Therapeutics, Inc.
• ImmunityBio, Inc.
• AVM Biotechnology Inc